Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 354

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 19
Chunk 354
---
 1,379,640      0.68      ( 3,825,990       0.53  
  Forfeited                             ( 3,121,894                  0.73      ( 2,424,535      0.21      ( 27,389,565      0.23  
  Exercised                             ( 162,599                    0.10      ( 493,238        0.22      ( 770,025         0.14  
  Outstanding at end of year*           89,871,858                   0.44      150,429,825      0.32      141,634,245       0.32  
  Exercisable at end of year            26,663,961                   0.78      51,970,635       0.54      88,080,600        0.40  

  As of December 31, 2022, 2023 and 2024, includes 10,482,277, 12,219,465, and 4,010,670 PSUs at an exercise price of 0.10 NIS (par value of ordinary shares), for which performance obligations ha...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

The total consideration received from the exercise of equity instruments during 2022, 2023 and 2024 was not material.

Set forth below is data regarding the range of exercise prices and weighted-average remaining contractual life (in years) for the equity instruments outstanding at the end of each of the years indicated.

As of December 31,
As of December 31,
2023 2024
2023 2024
Range of Number Number

exercise of options of options

prices outstanding outstanding
Number Number
(in NIS) of options of options
Range of outstanding outstanding
exercise
prices
(in NIS)
────────────────────────────────────────────────────────────────────────────────────────────────────────────
Up to 0.49 120,593,415 8.8 114,352,425 8.07
0.5-0.99 16,147,110 6.9 15,104,100 6.54
1.00-2.00 13,149,390 4.7 11,727,